746 related articles for article (PubMed ID: 17919894)
1. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
[TBL] [Abstract][Full Text] [Related]
3. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
5. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
[TBL] [Abstract][Full Text] [Related]
8. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
9. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of combined therapy for type 2 diabetes.
Rodríguez A; Ciprés L; Tofé S; Polavieja P; Reviriego J
Curr Med Res Opin; 2010 May; 26(5):1171-83. PubMed ID: 20297952
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
14. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
[TBL] [Abstract][Full Text] [Related]
15. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study.
Matthews DR; Charbonnel BH; Hanefeld M; Brunetti P; Schernthaner G
Diabetes Metab Res Rev; 2005; 21(2):167-74. PubMed ID: 15386821
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Lester JW; Fernandes AW
Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
[TBL] [Abstract][Full Text] [Related]
18. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
Seufert J
Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
[TBL] [Abstract][Full Text] [Related]
19. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
Elkeles RS
Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
[TBL] [Abstract][Full Text] [Related]
20. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
